多示踪剂PET分期模型评估皮层淀粉样蛋白沉积
该模型在超过3000例中成功分类淀粉样蛋白负荷,并能识别全局阳性前的沉积及全局阳性个体中不同的认知下降风险。
要点
- 多示踪剂 pooled 分期模型可跨队列和示踪剂对淀粉样蛋白负荷进行分期。
- 分期越高,向MMSE≤25进展的风险越高。
- 该模型能检测全局淀粉样蛋白阳性前的沉积。
核心结论
- 多示踪剂 pooled 分期模型成功在超过3000例跨队列和示踪剂的个体中分类淀粉样蛋白负荷。
- 该模型可检测全局淀粉样蛋白阳性前的负荷,并识别全局阳性个体中不同的认知下降风险特征。
研究设计与样本
- 基于400例认知未受损个体(每种示踪剂100例)的异常频率构建单示踪剂和 pooled 多示踪剂区域排序。
- pooled 多示踪剂排序用于创建包含4个区域簇的分期模型。
主要发现
- SUVr异常最常出现在扣带回,其次为眶额、楔前叶和岛叶皮层,然后是联合、颞和枕区。
- 基于二分类全局SUVr的异常淀粉样蛋白水平在分期0至4中分别占1.0%、5.5%、17.9%、90.0%和100.0%。
- 基线分期预测MMSE评分下降(ADNI:n=867,F=67.37,p<0.001;OASIS:n=475,F=9.12,p<0.001)。
- 基线分期预测向MMSE≤25的更快进展(ADNI:n=787,HRstage1 2.00,HRstage2 3.53,HRstage3 4.55,HRstage4 9.91,p<0.001;OASIS:n=469,HRstage4 4.80,p<0.001)。
关键数值与推荐
- 分期模型由4个区域簇组成。
- 基于二分类全局SUVr的异常淀粉样蛋白水平在分期0至4中分别占1.0%、5.5%、17.9%、90.0%和100.0%。
临床怎么用
- 该分期模型可用于跨示踪剂和队列对淀粉样蛋白负荷进行分期。
- 分期结果有助于识别全局淀粉样蛋白阳性个体中不同的认知下降风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop and evaluate a model for staging cortical amyloid deposition using PET with high generalizability. METHODS: Three thousand twenty-seven individuals (1,763 cognitively unimpaired [CU], 658 impaired, 467 with Alzheimer disease [AD] dementia, 111 with non-AD dementia, and 28 with missing diagnosis) from 6 cohorts (European Medical Information Framework for AD, Alzheimer's and Family, Alzheimer's Biomarkers in Daily Practice, Amsterdam Dementia Cohort, Open Access Series of Imaging Studies [OASIS]-3, Alzheimer's Disease Neuroimaging Initiative [ADNI]) who underwent amyloid PET were retrospectively included; 1,049 individuals had follow-up scans. With application of dataset-specific cutoffs to global standard uptake value ratio (SUVr) values from 27 regions, single-tracer and pooled multitracer regional rankings were constructed from the frequency of abnormality across 400 CU individuals (100 per tracer). The pooled multitracer ranking was used to create a staging model consisting of 4 clusters of regions because it displayed a high and consistent correlation with each single-tracer ranking. Relationships between amyloid stage, clinical variables, and longitudinal cognitive decline were investigated. RESULTS: SUVr abnormality was most frequently observed in cingulate, followed by orbitofrontal, precuneal, and insular cortices and then the associative, temporal, and occipital regions. Abnormal amyloid levels based on binary global SUVr classification were observed in 1.0%, 5.5%, 17.9%, 90.0%, and 100.0% of individuals in stage 0 to 4, respectively. Baseline stage predicted decline in Mini-Mental State Examination (MMSE) score (ADNI: n = 867, F = 67.37, p < 0.001; OASIS: n = 475, F = 9.12, p < 0.001) and faster progression toward an MMSE score ≤25 (ADNI: n = 787, hazard ratio [HR]stage1 2.00, HRstage2 3.53, HRstage3 4.55, HRstage4 9.91, p < 0.001; OASIS: n = 469, HRstage4 4.80, p < 0.001). CONCLUSION: The pooled multitracer staging model successfully classified the level of amyloid burden in >3,000 individuals across cohorts and radiotracers and detects preglobal amyloid burden and distinct risk profiles of cognitive decline within globally amyloid-positive individuals.
引用
- Collij LE, Heeman F, Salvadó G, et al. Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology. 2020. PMID: 32675080. doi:10.1212/WNL.0000000000010256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。